Literature DB >> 32893180

Review of SMARCA4 (BRG1)-deficient carcinomas following a malignant pleural effusion specimen confounded by reduced claudin-4 expression.

Caroline A Early1, Sintawat Wangsiricharoen1, Robert M Jones1, Christopher J VandenBussche2.   

Abstract

SMARCA4-deficient neoplasms are recently characterized high-grade malignancies associated with a poor prognosis. The SMARCA4 gene encodes BRG1, which is part of the SWI/SNF complex. SMARCA4-deficient neoplasms have an undifferentiated, often rhabdoid morphology, and demonstrate loss of BRG1 nuclear expression on immunohistochemistry. These neoplasms have become increasingly recognized and diagnosed in tissue specimens, but their features in cytologic specimens are poorly defined in the literature. The review is introduced by a diagnostically challenging case of a SMARCA4-deficient carcinoma involving a pleural fluid specimen in which the carcinoma cells demonstrated greatly reduced claudin-4 expression in the setting of strong, diffuse BerEP4 expression. Most of the malignant cells also demonstrated positive cytoplasmic staining for PAS and all were PAS-diastase negative, suggesting that the cytoplasm contained glycogen granules.
Copyright © 2021 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRG1; Cancer; INI1; Pleural fluid; Poorly differentiated carcinoma; SMARCA4

Mesh:

Substances:

Year:  2020        PMID: 32893180     DOI: 10.1016/j.jasc.2020.08.002

Source DB:  PubMed          Journal:  J Am Soc Cytopathol        ISSN: 2213-2953


  2 in total

1.  SMARCA4-deficient rectal carcinoma with a sarcomatoid component: a case report.

Authors:  Yuki Meda; Hideo Miyake; Hidemasa Nagai; Yuichiro Yoshioka; Norihiro Yuasa; Ayami Kiriyama; Masahiko Fujino
Journal:  Clin J Gastroenterol       Date:  2022-02-07

2.  Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review.

Authors:  Huanli Duan; Wei Gao; Leiming Wang; Feng Cao; Lianghong Teng
Journal:  Diagn Pathol       Date:  2021-04-09       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.